Biotest

Biotest Current Liabilities

Delisted

The Current Liabilities of Biotest (BIO.DE) as of Nov 6, 2026 is 191.30 M EUR. In the previous year, Current Liabilities was 644.20 M EUR — a change of -70.30% (lower).

Current Liabilities

191.30 MEUR

YoY

-70.30%

Last updated:

Current Liabilities of Biotest is 2024 191.30 M EUR. Current Liabilities of Biotest was 2023 644.20 M EUR. It decreases by -70.30% lower compared to the previous year.

The Biotest Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
288.20 M EUR
Jan 1, 2018
118.90 M EUR
Jan 1, 2019
18.90 M EUR
Jan 1, 2020
109.70 M EUR
Jan 1, 2021
92.00 M EUR
Jan 1, 2022
167.40 M EUR
Jan 1, 2023
644.20 M EUR
Jan 1, 2024
191.30 M EUR
The Biotest Current Liabilities history
YEARCurrent LiabilitiesYoY
191.30 MEUR-70.30%
644.20 MEUR+284.83%
167.40 MEUR+81.96%
92.00 MEUR-16.13%
109.70 MEUR+480.42%
18.90 MEUR-84.10%
118.90 MEUR-58.74%
288.20 MEUR+83.92%
156.70 MEUR+23.39%
127.00 MEUR+2.50%
123.90 MEUR+9.94%
112.70 MEUR-43.98%
201.19 MEUR+29.22%
155.70 MEUR+1.64%
153.19 MEUR-20.14%
191.82 MEUR+35.22%
141.86 MEUR+636.05%
19.27 MEUR+61.50%
11.93 MEUR-27.61%
16.49 MEUR-85.69%
115.21 MEUR+8.48%
106.20 MEUR-7.41%
114.70 MEUR-0.22%
114.96 MEUR+26.09%
91.18 MEUR+36.53%
66.78 MEUR+3.53%
64.51 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

Current Liabilities of Biotest is 191.30 M EUR in 2024.

Current Liabilities of Biotest changed from 644.20 M EUR to 191.30 M EUR, representing a -70.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Biotest since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Biotest historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biotest

All Key Metrics — Biotest